Share Repurchase Announcement: GIANT BIOGENE plans to repurchase up to 104 million shares, representing 10% of its issued shares, and aims to enhance its product matrix, brand operations, and channel development by 2026.
Management Confidence: CICC views the buyback as a sign of management's confidence, highlighting the company's strong R&D capabilities and brand recognition, which are expected to drive operational improvements and growth in the medical beauty sector.
Target Price Adjustment: BofAS has reduced GIANT BIOGENE's target price by 20% to HKD56 while maintaining an Outperform rating, indicating a cautious outlook despite the company's potential.
Short Selling Data: The company has reported short selling of $87.94 million, with a ratio of 16.967%, reflecting market sentiment and trading activity surrounding its stock.
Wall Street analysts forecast 02367 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02367 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 02367 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02367 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 36.040
Low
Averages
High
Current: 36.040
Low
Averages
High
CMSI
CMSI
Buy
to
Neutral
downgrade
$64
Al Analysis
2025-12-23
Reason
CMSI
CMSI
Price Target
$64
Al Analysis
2025-12-23
downgrade
Buy
to
Neutral
Reason
The analyst rating for GIANT BIOGENE (02367.HK) was downgraded from Buy to Neutral due to a public relations crisis that has shifted the investment logic from growth to strategic adjustment. The company is expected to enter an adjustment period in 2026 without any catalysts, and CMSI has revised its net profit forecast for GIANT BIOGENE to be 12% lower than market expectations, cutting the forecast by over 30% on average. Additionally, the target price was reduced from HKD 64 to HKD 34.5.
Morgan Stanley
Morgan Stanley
Overweight
to
Neutral
downgrade
$78 -> $42
2025-12-17
Reason
Morgan Stanley
Morgan Stanley
Price Target
$78 -> $42
2025-12-17
downgrade
Overweight
to
Neutral
Reason
The analyst rating for GIANT BIOGENE (02367.HK) was adjusted to "Neutral" by UBS, with a target price slashed to $39.5, primarily due to a significant downward revision in the company's sales guidance and revenue forecasts. Morgan Stanley's report indicated that the company adjusted its 2025 sales growth expectation from 25% to flat or a mild decline, influenced by industry headwinds that hindered previously projected growth during key periods. Additionally, Morgan Stanley revised its revenue forecasts for 2025-27 down by 20%, 32%, and 35%, respectively, and anticipated a net profit drop of 8% year-over-year in 2025 and 2026, although a rebound of 20% was expected in 2027. The overall sentiment reflects concerns about the company's ability to achieve its growth targets amidst these challenges.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 02367
Unlock Now
UBS
UBS
Buy
to
Neutral
downgrade
2025-12-11
Reason
UBS
UBS
Price Target
2025-12-11
downgrade
Buy
to
Neutral
Reason
The analyst rating downgrade from Buy to Neutral for GIANT BIOGENE (02367.HK) by UBS is primarily due to increased uncertainty over the company's short-term revenue and profit outlook. UBS has also lowered its earnings forecasts for 2025-2027 by 25-41% and reduced revenue forecasts for the same period by 20-36%. Additionally, the report highlights intensified market competition from other skincare brands offering more attractive pricing and using similar core ingredients, which adds to the uncertainty regarding the success of GIANT BIOGENE's new products in the upcoming year.
Bank of America Securities
BofAS
Buy
downgrade
2025-12-05
Reason
Bank of America Securities
BofAS
Price Target
2025-12-05
downgrade
Buy
Reason
The analyst rating for GIANT BIOGENE (02367.HK) was kept as "Buy" despite a reduction in the target price from HKD 69.3 to HKD 46.4. This decision was influenced by the downward revision of earnings expectations due to growth pressures on the Comfy brand, which led to a 17-25% decrease in the 2025-27 earnings forecasts. However, the potential positive impact of the medical beauty business in 2026 was noted as a catalyst that could support the company's performance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
